GP IIb/IIIa Inhibitors
3 drugsAbout GP IIb/IIIa
Glycoprotein IIb/IIIa (GP IIb/IIIa), also known as integrin αIIbβ3, is a receptor on platelets crucial for aggregation and thrombus formation by binding fibrinogen and other ligands. Inhibition of this receptor blocks platelet aggregation, making it a significant drug target in cardiovascular therapeutics.
GP IIb/IIIa is strongly genetically validated (max score 0.97), with loss-of-function variants in ITGB3 linked to Glanzmann thrombasthenia and other bleeding disorders. Activation of GP IIb/IIIa is likely beneficial based on genetic evidence, suggesting potential for novel therapies.
GP IIb/IIIa is targeted by 3 FDA-approved drugs, including Eptifibatide (Integrilin) and Tirofiban hydrochloride (Aggastat), with small molecules (2 drugs) and peptides (1 drug) as modalities. These drugs are all indicated for cardiovascular conditions.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Vessel Occlusion with only 1 trials.
GP IIb/IIIa Genetic Evidence Strong
GP IIb/IIIa has strong genetic support with a max score of 0.97 linked to Glanzmann thrombasthenia.
Strong genetic support increases the likelihood of clinical success, warranting further investment in GP IIb/IIIa-targeted therapies.
💡 Why activation?
- • Loss-of-function variants increase disease risk (OR > 1) — restoring function may help
- • 100% directional consistency across 3 traits
- • Strong signal in hematologic disease, genetic, familial or congenital disease pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
20 totalGWAS and other genetic studies link ITGB3 to 22 diseases.
Loss-of-function causes disease; activation may help
Loss-of-function causes disease; activation may help
🔗 Colocalization Evidence 13 strong
max H4: 0.99eQTL/pQTL signals for ITGB3 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top GP IIb/IIIa Drugs
Three companies, including Slate Run Pharma and Medicure, have approved drugs targeting GP IIb/IIIa.
The limited number of companies suggests relatively low barriers to entry, but also a concentrated market.
GP IIb/IIIa Drug Modality Landscape
Modalities
Routes of Administration
GP IIb/IIIa is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities beyond small molecules and peptides could offer a competitive advantage in the GP IIb/IIIa space.
GP IIb/IIIa Clinical Trials 35 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 5 | 2 | 2 | 1 | 50% |
| Phase 2 | 11 | 8 | 1 | 2 | 89% |
| Phase 3 | 10 | 4 | 0 | 6 | 100% |
| Phase 4 | 9 | 7 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
GP IIb/IIIa Drug Approval Timeline (1998 - 2021)
The first GP IIb/IIIa-targeting drug was approved in 1998, with the most recent approval in 2021.
The approval timeline indicates continued interest in GP IIb/IIIa as a target, but also potential market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 41 clinical trials targeting GP IIb/IIIa.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities